

# **MI COVID RESPONSE DATA AND MODELING UPDATE**

August 23, 2022

# Epidemiologic Surveillance: Key Messages

## **COVID-19 pandemic is decreasing in some parts of the globe and within the United States**

- Case rates for several European countries are declining with early signs of plateaus
- Within the U.S., case rates decreased 9.9% over the past week
- Nearly all midwestern states (region 5) are showing signs of a plateau

## **COVID spread in Michigan is slowly increasing**

- COVID spread is assessed from many different markers including CDC community levels and other surveillance systems
- As of Aug 18, 75% of Michigan counties are at medium or high COVID-19 community levels, which is higher than last week
  - 18 Michigan counties are classified as High this week according to CDC's Community Levels (22%). This represents 56% of the population.
  - 44 Michigan counties are currently at Medium level (53%). This represents 31% of the population
- The  $R_t$  for Michigan is slightly above 1 indicating COVID is steadily increasing
- The proportion of specimens sequenced and identified as BA.5 in the U.S. and Michigan continues to remain the most dominant
- SWEEP sites were equally split between increases and decreases in the most recent week

## **COVID-19 hospital metrics in Michigan remain lower than past surges**


- COVID-19 hospital admissions, hospital census, and ICU census showed small signs of increases this week compared to last week

# Global and National Trends


## Daily new confirmed COVID-19 cases per million people

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.

LINEAR LOG



Our World  
in Data



CC BY

**Globally, 596,275,297 cases and 6,454,097 deaths** (Data\* through 8/22/2022)

- Case rates for Europe continue to decline with some signs of plateaus


**United States: Reported cases (7-day average) have decreased 9.9% since the prior week<sup>†</sup>**

- In the U.S., the case rate is 197.7 cases/100,000 in last 7 days (last week: 217.4 cases per/100,000)

**Most Region 5 (Midwest) states are showing early signs of plateaus**


- Minnesota and Illinois have the lowest case rates in Region 5 (8/22/2022)

# Local Prevention Decisions Should Use Community Levels in Concert with Other Pandemic Indicators





# As of Aug 18, 18 Michigan Counties at High COVID-19 Community Level




- In the US, 34% of counties have high risk for medically significant disease and healthcare strain
- In Michigan, 22% (18/83) of counties are at high risk. This represents 56% of the population
- 44 Michigan counties are currently at Medium level (53%). This represents 31% of the population
- 21 Michigan counties are currently at Low level (25%). This represents 13% of the population

## Percent of Counties



	United States	Michigan	Percent of MI Population
Low	25%	25%	13%
Medium	41%	53%	31%
High	34%	22%	56%

Low	Medium	High
<ul style="list-style-type: none"><li>• Stay <a href="#">up to date</a> with COVID-19 vaccines</li><li>• <a href="#">Get tested</a> if you have symptoms</li></ul>	<ul style="list-style-type: none"><li>• If you are <a href="#">at high risk for severe illness</a>, talk to your healthcare provider about whether you need to wear a mask and take other precautions</li><li>• Stay <a href="#">up to date</a> with COVID-19 vaccines</li><li>• <a href="#">Get tested</a> if you have symptoms</li></ul>	<ul style="list-style-type: none"><li>• Wear a <a href="#">mask</a> indoors in public</li><li>• Stay <a href="#">up to date</a> with COVID-19 vaccines</li><li>• <a href="#">Get tested</a> if you have symptoms</li><li>• Additional precautions may be needed for people <a href="#">at high risk for severe illness</a></li></ul>

# Cases are plateaued/slightly increasing in Michigan




36 counties currently showing increases and 11 in elevated incidence plateaus (via [mystartmap.info](https://mystartmap.info) as of 8/19/22, data through 8/12/22).




# Recent Statewide and Regional Trends

## Statewide trends


Positivity, %




Daily cases per million




Daily hospitalization rate, %



Deaths




## MERC Regional breakdown: Positivity, cases, hospitalization rate, and deaths



# Scenario Hub projections suggest plateau/smaller fall surge + potential winter surge

- Explored scenarios with early/late boosters and potential new variant
- Fall: smaller surge or plateau
- Winter
  - If no new immune escape variant, suggests plateau through winter (left two plots)
  - If new variant, potential for larger winter surge (right two plots)
- Similar patterns for cases and deaths (see link below)




Plotted with 50% uncertainty interval

Source: [Round 15 Scenario Modeling Hub Projections](#)



# Case Rates by Age, Race, and Ethnicity

Daily new confirmed and probable cases per million by age group (7-day rolling average)



- Case rates by onset date for all age groups are between 117.6 and 303.5 cases per million (through 8/12)
- Case counts and case rates are highest for 30-39-year-olds this week, followed by 20-29-year-olds and the 80+-year-old age groups

Daily new confirmed and probable cases per million (7 day rolling average) by race & ethnicity category



- Case rates are highest for Black populations (190.0 cases/million)
- Between 22-27% of cases in last 30 days have missing race/ethnicity data


Note: Case information sourced from MDHHS and reflects date of onset of symptoms  
Source: MDHHS – Michigan Disease Surveillance System

# COVID case counts among K-12 age individuals have increased slightly

Intermediate School Districts School Districts About

## Michigan School District COVID-19 Case Reporting

The map below displays the 7-day average of newly reported COVID-19 cases for school aged residents (ages 5 to 18 years) by their Michigan school district. The geocoding is based on the residential address on record and not the student's enrollment. The 7-day case average for the defined date range can be viewed by hovering over the jurisdiction on the map or by selecting the school district from the drop down list in the right panel. Adjusting the date scale will change the 7-day average on the map for the selected date.




Data Source: Michigan Disease Surveillance System (MDSS)  
Last Updated: 8/23/2022

- K-12 age population summary:**
- Overall case counts among school-aged populations are plateaued (7-day average 146.7)
  - 52% of school district areas have between 1-5 cases.
  - 3 ISD areas have greater than 5 cases.




# Identified COVID-19 Cases Caused by Variants of Concern (VOC) in US and Michigan

## SARS-CoV-2 Variants Circulating in the United States, Jun 5 – Aug 13 (NOWCAST)



## VOC Distribution in Michigan



- Since July 15, there have 2117 VOC specimens sequenced
- 100% of specimens sequenced are Omicron, 83% of those are BA.5 lineage
  - In the most recent week (July 31 – Aug 6), a majority of specimens sequenced are BA.5 (85.3%) with 461 specimens collected and reported to date

# Interpreting Wastewater Should Be In Context with Other Indicators

- When levels of virus in wastewater are low, a modest increase overall in virus level can appear much larger as numbers are translated into percentages
- This does not necessarily mean we will see major increases in transmission in the community
- When increases are seen within one wastewater site, public health officials compare with neighboring communities and other data sources to understand potential of surges
- For example, the Ypsilanti WWTP saw increases in SARS-CoV-2 levels which correlated with increasing presence of Omicron BA.2 lineage and then followed by an increase in cases

## Ypsilanti WWTP

The most recent sample concentration is higher than 86% of samples collected at this site, which puts it in the 81-100 percentile category. As of 7/27/2022, the change in viral concentration over the past 15 days is increasing.


## Wastewater SARS-CoV-2 Levels and COVID-19 Cases



The blue line on the graph shows the levels of SARS-CoV-2, the virus that causes COVID-19, in the wastewater samples collected from Ypsilanti WWTP. Each data point is calculated by averaging the number of viral gene copies detected per 100mL of wastewater in the 3 most recent samples. The orange bars on the graph show the COVID-19 cases reported to MDHHS from the zip codes that the wastewater treatment plant serves (7-day average). Both the virus levels and COVID-19 cases are calculated per 100,000 people. Case data will not be shown on the graph when the average number of cases is fewer than 10 per 100,000 people to protect the confidentiality of individuals with infections. This will be represented by an orange dashed line with gray shading below.

# Michigan COVID-19 SWEEP Sentinel Wastewater Dashboard

The map below shows 20 sewershed sites in Michigan where wastewater is being monitored for the presence of SARS-CoV-2, the virus that causes COVID-19. These sentinel sites serve as a subset of wastewater surveillance in Michigan distributed across the Michigan Economic Recovery Council (MERC) Regions. Click on each site on the map to see wastewater and clinical case data over time. To view wastewater data from previous weeks, please use the "Map - All Data" and "Trends - All Data" tabs.




Site	Sewershed Population	Consecutive Weeks of Virus Detection	Trend As Of	15-Day Trend
Alma WWTP	8976	17	8/8/2022	↑
Battle Creek WWTP	51093	17	8/10/2022	↑
Bay City WWTP	34000	8	8/10/2022	↑
Delhi Township WWTP	22500	19	8/4/2022	↓
Escanaba WWTP	12600	15	8/10/2022	↓
GLWA Detroit River Interce..	492000	95	8/10/2022	↓
GLWA North Interceptor-Ea..	1482000	72	8/10/2022	↓
GLWA Oakwood-Northwest..	840600	95	8/10/2022	↓
Grand Rapids WWTP	265000	53	8/8/2022	↑
Holland WWTP North	45606	17	8/10/2022	↑
Holland WWTP South	36912	19	8/10/2022	↑
Jackson WWTP	90000	56	8/11/2022	↓
Kalamazoo WWTP	150000	20	8/11/2022	↓
Petoskey WWTP	7900	17	8/11/2022	↓
Portage Lake WWTP	14000	48	8/10/2022	↑
Saginaw Township WWTP	40000	18	8/10/2022	↑
Tecumseh WWTP	8680	31	8/12/2022	↓
Traverse City WWTP	45000	22	8/11/2022	↑
Warren WWTP	135000	16	8/4/2022	↑
Ypsilanti WWTP	330000	56	8/10/2022	↓

Abbreviations: GLWA - Great Lakes Water Authority; WWTP - Waste Water Treatment Plant

Definitions and descriptions of data calculations can be found in the "About" tab.


Current results reflect data that were uploaded to MDHHS as of 8/17/2022. Labs are required to report test results to local partners within 24 hours. Data is subject to change as additional wastewater data and case data are received.



## SWEEP Summary

- 50% (10/20) of sentinel sites are showing increasing trends over last 15-days
- 50% (10/20) of sentinel sites are showing declines in the previous 15-days

# Reported Number of Clusters in Long Term Care Facilities




- The number of Long-Term Care Facilities reporting 3 or more cases within a single reporting period is steadily increasing over the past month
- This week, the number has increased in both **AFC/HFAs** (18 to 24) and in **SNFs** (37 to 38) since the previous week


The data is from weekly reporting by facilities with bed occupancy of at least 13 beds.

# Cases Among Staff and Residents in Long Term Care Facilities

STATE OF MICHIGAN WEEKLY TOTAL CONFIRMED COVID-19 CASES IN  
AFC/HFA RESIDENTS AND STAFF  
08/18/2021 TO 08/16/2022



STATE OF MICHIGAN WEEKLY TOTAL CONFIRMED COVID-19 CASES IN  
SNF  
RESIDENTS AND STAFF  
08/20/2021 TO 08/19/2022




- Case counts in residents are increased in AFC/HFA (141 to 186), but decreased in SNFs (332 to 311) since last week
- Case counts in staff are plateaued within AFC/HFA (201), and SNFs (480) since last week
- **29%** of SNFs are reporting **nursing shortages** and **30%** of SNFs are reporting **aide shortages**, which is stable from last week

Abbreviations: AFC: Adult Foster Care; HFAs: Homes for the Aged; and SNF: Skilled Nursing Facilities



# Hospital admissions due to COVID-19



- Trends for daily average hospital admissions were steady (+2%) compared to last week (vs. +1% prior week)
- Only older age groups (50-59, 70-79, and 80+) saw an increase this week compared to last week
- Those 60-69, 70-79, and 80+ are seeing between 27-45 daily hospital admissions



# Hospital Admissions and Admission Rates by Age Group

Daily new hospital admission per million by age group (7-day rolling average)

Age Group	Average† daily number of hospital admissions	Average† Daily Hospital Admission Rate*	One Week % Change (Δ #)
0-11	6.0	4.3	-9% (-1)
12-17	1.3	1.7	-10% (-<1)
18-19	0.6	2.2	-60% (-1)
20-29	7.6	5.5	-13% (-1)
30-39	9.6	7.9	-29% (-4)
40-49	9.7	8.2	-8% (-1)
50-59	18.4	13.6	+33% (+5)
60-69	<b>27.1</b>	<b>21.3</b>	-10% (-3)
70-79	<b>36.6</b>	<b>47.7</b>	+1% (+<1)
80+	<b>45.1</b>	<b>109.0</b>	+18% (+7)
<b>Total¶</b>	<b>163.7</b>	<b>14.4</b>	<b>+2% (+3)</b>

\* Rate per 1 million residents; † Rolling 7-day average; ¶ Total may not reflect state due to missing age data

Note: Hospital Admission data reflects date data was submitted


Source: CHECC and EM Resource

- Through August 22, there were an average of 163.7 hospital admissions per day due to COVID-19; an increase from last week (+2%, +3)
- Only older age groups (50-59, 70-79, and 80+) saw an increase this week compared to last week
- This week, those between 80+ years (+7/day) saw the greatest daily average increase
- Average daily hospital admission count (45.1 hospital admissions per day) and average daily hospital admission rate (109.0 hospital admissions/million) was highest among those aged 80+
- Those 60-69, 70-79, and 80+ are seeing between 25-45 daily hospital admissions

Note: for some age groups, small changes in number of hospitalization admissions can cause large change in One Week Percent Change


# Statewide Hospitalization Trends: Total COVID+ Census

Hospitalization Trends 7/1/2021 – 8/22/2022  
Confirmed Positive & Persons Under Investigation (PUI)




COVID+ census in hospitals increased slightly from last week, by 3%. Overall census is currently 1,070 patients.

Hospitalized COVID Positive Long Term Trend (beginning March 2020)



# Statewide Hospitalization Trends: Regional COVID+ Census

Hospitalization Trends 7/1/2021 – 8/22/2022  
Confirmed Positive by Region




This week hospitalizations have increased in Regions 2N, 2S, 3, 6, 7, and 8. Hospitalizations have decreased or remained flat in Regions 1 and 5.

Regions 2N, 2S, 3, AND 8 have greater than or equal to 100/million population hospitalized with COVID.

Region	COVID+ Hospitalizations (% Δ from last week)	COVID+ Hospitalizations / MM
Region 1	67 (-15%)	62/M
Region 2N	278 (10%)	126/M
Region 2S	330 (2%)	148/M
Region 3	138 (2%)	122/M
Region 5	78 (-7%)	82/M
Region 6	112 (3%)	76/M
Region 7	36 (6%)	72/M
Region 8	31 (55%)	100/M

# Statewide Hospitalization Trends: ICU COVID+ Census

Hospitalization Trends 7/1/2021 – 8/22/2022  
Confirmed Positive in ICUs



Overall, the volume of COVID+ patients in ICUs has increased by 12% from last week. There are 123 COVID+ patients in ICU beds across the state.

ICU occupancy is greater than 85% in Regions 1 and 3. All regions have fewer than 10% of ICU beds occupied by COVID+ patients.

Region	Adult COVID+ in ICU (% Δ from last week)	ICU Occupancy	% of ICU beds COVID+
Region 1	11 (-15%)	89%	6%
Region 2N	30 (67%)	66%	5%
Region 2S	42 (8%)	75%	6%
Region 3	13 (-24%)	86%	4%
Region 5	8 (100%)	69%	4%
Region 6	9 (-25%)	72%	4%
Region 7	7 (17%)	82%	5%
Region 8	3 (200%)	56%	5%


# Severity: Recent months have seen the lowest % of hospitalizations in the ICU over the entire pandemic



- Testing, hospitalizations, and ICU usage have all changed substantially over the pandemic
- Currently seeing lower % of hospitalizations in the ICU compared to earlier in the pandemic, likely due in part to vaccination and increased availability of treatment

# Statewide Hospitalization Trends: Pediatric COVID+ Census

Hospitalization Trends 1/1/2021 – 8/22/2022  
Pediatric Hospitalizations, Confirmed






# Time Trends – Annual Comparison: Percent Inpatient COVID+


- The percent of inpatients who are COVID+ remains lower than Alpha, Omicron, and holiday wave peaks
- Current hospital levels are higher than last summer's levels as we head into the fall

## 7-day rolling average of percent of inpatients who are COVID positive




# Average new deaths has plateaued for those over the age of 80

Daily COVID-19 deaths in confirmed and probable cases per million by age group (7 day rolling average)



Total COVID-19 deaths in confirmed and probable cases by age group (past 30 days, ending 8/12/2022)

- 8.0% of deaths below age sixty



- Through 8/12, the 7-day avg. death rate has plateaued (13.6 deaths per million people) for those over the age of 80
- In the past 30 days, there are fewer than 10 confirmed and probable COVID-19 deaths under the age of 50
- 30-day proportion of deaths among those under 60 years of age is 8.0%.

Note: Death information sourced from MDHHS and reflects date of death of confirmed and probable cases.  
Source: MDHHS – Michigan Disease Surveillance System (MDSS)

# Harm Reduction: Key Messages

**Empowering community members to make best choices for their individual circumstances and to be prepared by making a COVID plan**

- Michiganders can take advantage of local, state, and national COVID-19 resources
- Get tested, and if positive, seek care with therapeutics (e.g., antibodies or antiviral medications)
  - Cumulative therapeutic availability and administration is increasing since end of June
  - Talk to your doctor or pharmacist about whether you should get antibody or antiviral treatment, and where you can find treatment
  - Therapeutics are authorized for people who meet select criteria
  - Additional public health, regulatory, and policy efforts might help decrease barriers to oral antiviral access, particularly in communities with high social vulnerability
- Vaccinations remain the best way to protect from COVID-19, especially from severe disease
  - COVID-19 vaccines are now available for ages 6 months and up
    - Everyone 6 months and older should also get an age-appropriate COVID-19 booster, when eligible
  - Data tracker now includes Novavax administration
  - Over 6.7 million Michiganders have received at least one dose (67.9%)
  - 56.1% of fully vaccinated Michiganders have received at least one booster
  - 33.3% of people in Michigan (723K+) with a first booster dose have received a second booster dose


## Federal & Michigan websites assist COVID positive residents find treatment

COVID-19 resources available on federal website: [COVID.gov](https://www.covid.gov)

# Test-to-Treat program simplifies access to COVID treatment:

[Find a Test-to-Treat location near you](#)

- If you have COVID-19 symptoms, do not wait to get treated
- You must take oral COVID-19 medication within 5 days of your first COVID-19 symptoms
- Use the tool to find a location that is right for you



Source: Screen capture of Michigan Test-to-Treat sites from linked website

Therapeutic administration increased during Michigan's Spring Omicron surge. Supply limitations in January 2022 required strategic distribution and should not be compared directly.

Source: HHS – Tiberius


\*Data is reported as a single patient course, except for Evusheld, which is reported as the number of 300mg doses administered. Data Updated August 5

# COVID-19 Rebound after Paxlovid Treatment

- Paxlovid is a prescription oral antiviral drug that reduces risk of hospitalization and death for patients with mild to moderate COVID-19 who are at higher risk of disease progression and severe illness
  - Treatment should be initiated as soon as possible and within 5 days of symptom onset among eligible individuals
- Following Paxlovid treatment, **COVID-19 rebound** has been reported to **occur between 2 and 8 days after initial recovery** and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative
- To date, there is limited information available from case reports who have experience COVID-19 rebound
  - There are **no reported cases of severe disease following COVID-19 rebound**
  - Currently, **no evidence that additional treatment is needed** with Paxlovid or other anti-SARA-CoV-2 therapies in cases where COVID-19 rebound is suspected
  - There is the possibility of transmission of infection during COVID-19 rebound and those experience rebound should continue to follow CDC's guidance on isolation
    - People with rebound should restart isolation and isolate again for at least 5 days
- Providers and patients can get more information from [CDC and FDA](#)

# Vaccinations and Boosters

- Over 16.6 million COVID-19 vaccine doses have been administered in Michigan
  - Over 6.7 million Michiganders have received at least one dose (67.9%)
  - Over 6 million Michiganders have completed a primary series (61.0%)
  - Over 3.4 million additional/booster doses have been administered in Michigan
    - 56.1% of the fully vaccinated population has received a booster
    - 77.8% of the fully vaccinated population 65 years of age or older has received a booster
- Nearly 723,344 Michiganders 50 years of age or older who have received a first booster dose have received second booster (33.3%)



**Note:** Cumulative data and population percentages now include those ages 6 months and older

**Sources:** Michigan Coronavirus Vaccine Dashboard; CDC COVID-19 Data Tracker: Vaccine Coverage Dashboard



# Person–, household–, and community level public health strategies to minimize COVID-19 impact (1 of 4)

- Summary guidance and links to scientific evidence
- Includes vaccination, PREP, treatment, ventilation, facial coverings, testing, isolation, close contacts, hand hygiene, and other NPIs

Recommended public health strategy	Person- and household-level prevention behaviors	Community-level prevention strategies*	Links to guidance and scientific evidence
COVID-19 vaccination	Stay up to date with COVID-19 vaccination	Distribute and administer vaccines to achieve high community vaccination coverage and ensure health equity Support community partnerships and leverage trusted sources of information to expand booster coverage	Vaccines for COVID-19: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html</a> Stay up to date with COVID-19 vaccines: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html</a> Science brief: COVID-19 vaccines and vaccination: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html</a>
Preexposure prophylaxis	Persons who are moderately or severely immunocompromised might benefit from COVID-19 preexposure prophylactic treatment (Evusheld) to prevent severe COVID-19 illness	Provide education and communication outreach to patients and clinical care organizations that serve patients with immunocompromising conditions to support equitable access to preexposure prophylaxis	COVID-19 preventive medication: <a href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#preventive">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#preventive</a> Prevention of SARS-CoV-2 infection: <a href="https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/">https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/</a>
Medications for treatment of COVID-19	Persons at increased risk for severe illness should have a plan for rapid access to tests and	Enable rapid access to oral COVID-19 treatment within ≤5 days of diagnosis Support clinical-community linkages to	COVID-19 treatments and medication: <a href="https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html">https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html</a>

# Person–, household–, and community level public health strategies to minimize COVID-19 impact (2 of 4)

- Summary guidance and links to scientific evidence
- Includes vaccination, PREP, treatment, ventilation, facial coverings, testing, isolation, close contacts, hand hygiene, and other NPIs

Recommended public health strategy	Person- and household-level prevention behaviors	Community-level prevention strategies*	Links to guidance and scientific evidence
Improved ventilation	Increase ventilation and filtration	Take steps to increase ventilation and filtration in public places	Improving ventilation in your home: <a href="https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/Improving-Ventilation-Home.html">https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/Improving-Ventilation-Home.html</a> Ventilation in buildings: <a href="https://www.cdc.gov/coronavirus/2019-ncov/community/ventilation.html">https://www.cdc.gov/coronavirus/2019-ncov/community/ventilation.html</a> Ventilation in schools and childcare programs: <a href="https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/ventilation.html">https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/ventilation.html</a> Science brief: SARS-CoV-2 transmission: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html</a>
Masks and respirators	Persons at high risk for severe illness should wear a mask or respirator (N95/KN95) that provides more protection indoors in public at medium and high COVID-19 community levels All persons should wear well-fitting masks or respirators indoors in public at high COVID-19 Community Levels†	Recommend all persons wear well-fitting masks or respirators at high COVID-19 Community Levels and support use of masks through messaging and resources	Masks and respirators: <a href="https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/types-of-masks.html">https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/types-of-masks.html</a> Science brief: community use of masks to control and spread of SARS-CoV-2: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html</a>

# Person–, household–, and community level public health strategies to minimize COVID-19 impact (3 of 4)

- Summary guidance and links to scientific evidence
- Includes vaccination, PREP, treatment, ventilation, facial coverings, testing, isolation, close contacts, hand hygiene, and other NPIs

Recommended public health strategy	Person- and household-level prevention behaviors	Community-level prevention strategies*	Links to guidance and scientific evidence
Managing exposures to SARS-CoV-2	Persons with recent exposure should wear a mask indoors in public for 10 days and test ≥5 days after last exposure	<p>Increase equitable access to testing, including through point-of-care and at-home tests for all persons</p> <p>Support case investigation and contact tracing in high-risk settings where recommended<sup>5</sup></p>	<p>What to do if you are exposed: <a href="https://www.cdc.gov/coronavirus/2019-ncov/your-health/if-you-were-exposed.html">https://www.cdc.gov/coronavirus/2019-ncov/your-health/if-you-were-exposed.html</a></p> <p>Definition of close contacts: <a href="https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html#contact">https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/appendix.html#contact</a></p> <p>Science brief: SARS-CoV-2 transmission: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html</a></p>
Hand hygiene	<p>Wash hands frequently</p> <p>mask around others at home and in public and avoid contact with persons at high risk for severe illness<sup>4</sup></p>	Ensure provision of adequate hand sanitation supplies	<p>How to protect yourself and others: <a href="https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html">https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html</a></p> <p>Science brief: SARS-CoV-2 transmission: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html</a></p>



# Person–, household–, and community level public health strategies to minimize COVID-19 impact (4 of 4)

- Summary guidance and links to scientific evidence
- Includes vaccination, PREP, treatment, ventilation, facial coverings, testing, isolation, close contacts, hand hygiene, and other NPIs

Recommended public health strategy	Person- and household-level prevention behaviors	Community-level prevention strategies*	Links to guidance and scientific evidence
Increasing space and distance	Persons at high risk for severe illness can consider avoiding crowded areas and minimizing direct physical contact, especially in settings where there is high risk for exposure	Provide education to populations at high risk for severe illness to advise them to consider taking steps to protect themselves in settings where there is high risk for exposure	How to protect yourself and others: <a href="https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html">https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html</a> Science brief: SARS-CoV-2 transmission: <a href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html</a>

\* Recommended strategies relate to general community settings; adapted setting-specific guidance and recommendations include schools and early childhood settings (<https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-childcare-guidance.html>), high-risk congregate settings such as correctional facilities and homeless shelters (<https://www.cdc.gov/coronavirus/2019-ncov/community/high-risk-congregate-settings.html>), health care settings (<https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html>), and travel (<https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html>).

† Although all masks and respirators provide some level of protection, properly fitting respirators provide the highest level of protection. Persons may consider the situation and other factors when choosing a mask or respirator that offers greater protection. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/types-of-masks.html#DifferentSituations>

§ Universal case investigation and contact tracing are not recommended for COVID-19; health departments and jurisdictions should prioritize investigation of COVID-19 cases, clusters, and outbreaks involving high-risk congregate settings such as long-term care facilities and correctional facilities or unusual clusters of cases. <https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/prioritization.html>

¶ Infected persons should end isolation only when they are without a fever for ≥24 hours without use of medication and all other symptoms have improved. Persons who had moderate illness from COVID-19, including those who show evidence of lower respiratory disease such as shortness of breath or difficulty breathing should isolate for ≥10 days. Persons who had severe illness from COVID-19 (including those who were hospitalized or required intensive care) and persons who are immunocompromised should consult with a health care provider about how to determine end of isolation. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>

# Take action if you test positive

**DAY 0**



**Everyone:**  
Stay home and away from others (isolate)

**People at high risk for severe illness:**  
Talk to your doctor about treatment

**End isolation on day 6 or later** if you never had symptoms or if you are fever-free for 24 hours and other symptoms improved



**Everyone through day 10:**

- Wear a mask OR use 2 negative antigen tests to decide when to stop wearing a mask
- Avoid people at high risk of getting very sick

**DAY 11 or later**

See CDC's isolation guidance for more info:  
[bit.ly/COVID19Isolation](https://bit.ly/COVID19Isolation)



**MMWR**

AUGUST 11, 2022

## Evidence Supporting CDC's New Isolation Recommendations

- Isolation is effective at reducing transmission of SARS-CoV-2<sup>1</sup>
- Symptomatic individuals with URI symptoms should isolate regardless of test result. Symptomatic individuals with an initial negative home antigen test result for SARS-CoV-2 should test again 1 to 2 days later because test sensitivity seems to peak several days after illness onset<sup>4</sup>
- SARS-CoV-2 transmission is propagated through high viral loads of viable virus which is found to be most evident earlier in infection through approximately day 8<sup>2,3</sup>
- Immunocompromised individuals may be infectious for longer periods of time<sup>2</sup>

**Abbreviations:** URI upper respiratory infection

**Sources:** 1. Massetti GM, Jackson BR, Brooks JT, et al. Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems — United States, August 2022. MMWR Morb Mortal Wkly Rep. ePub: 11 August 2022. DOI: <http://dx.doi.org/10.15585/mmwr.mm7133e1>

2. Rahmani A, Dini G, Leso V, Montecucco A, Kuszniir Vitturi B, Iavicoli I, Durando P. Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis. Med Lav. 2022 Apr 26;113(2):e2022014. doi: 10.23749/mdl.v113i2.12724. PMID: 35481581; PMCID: PMC9073762

3. Jefferson T, Spencer EA, Brassey Jon, Heneghan C, Viral Cultures for Coronavirus Disease 2019 Infectivity Assessment: A Systematic Review, Clinical Infectious Diseases, Volume 73, Issue 11, 1 December 2021, Pages e3884–e3899, <https://doi.org/10.1093/cid/ciaa1764>

4. Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern Med. 2022;182(7):701–709. doi:10.1001/jamainternmed.2022.1827

# CDC Operational Guidance for K-12 School and Early Childhood Education (ECE) Programs to Support Safe In-Person Learning

## Strategies for Everyday Operations in K-12 Schools and Early Childhood Education

- Schools and ECE programs should promote, emphasize, and implement a core set of infectious disease prevention strategies as part of their normal operations, including to mitigate COVID-19
  - Staying up to date on vaccinations
  - Staying home when sick
  - Improving ventilation
  - Washing hands and respiratory etiquette
  - Cleaning surfaces at least once a day

## Recently released CDC guidance to minimize COVID-19 impact in the United States modifies some of the existing mitigations in K-12 schools and ECEs

- Removed recommendation to cohort
- Changed recommendation to focus screening for high-risk activities during high COVID-19 Community level or in response to an outbreak
- Removed the recommendation to quarantine, except in high risk congregate settings
- Removed recommendation about Test to Stay in school settings
- Added detailed information about when to wear a mask\*, managing cases and exposures, and responding to outbreaks


## Considerations for Prioritizing Strategies

- COVID-19 community levels and other community or setting-specific context
  - Age of those in the population served
  - Students with disabilities
  - People at risk of getting very sick
  - Equity
  - Availability of resources
  - Communities served
  - Pediatric-specific considerations




# APPENDIX

# State Comparisons: Ohio and Indiana



# State Comparisons: Wisconsin and Michigan






# State Comparisons: Illinois and Minnesota

Illinois Confirmed New Cases / 1M (7 days average)





Minnesota Confirmed New Cases / 1M (7 days average)






# Michigan Trends of COVID-19 Community Levels

- As of August 18, 18 (22%) Michigan counties at high COVID-19 community level and another 44 Michigan counties are currently at Medium level (53%)
- The proportion of Michigan counties at medium and high is higher than last week
- Current levels are not as high as the first Omicron wave but are higher than the second Omicron (BA.2.12.1) wave



# Cases and hospitalization rates in many areas of MI have been near the level thresholds, leading to variability in the CDC Community Levels

- When an area is near 200 weekly cases/100K and 10 weekly admissions/100K, small changes in either metric can push areas to low, medium, or high levels
- Michigan statewide cases and hospital admissions have been near this intersection since late April/early May (see chart)
- Note CDC Community Levels are also determined by the % inpatient beds that are COVID+, however this metric has not reached the level thresholds yet (not shown)






# CDC COVID-19 Community Levels are defined by County Case Rates and Health Service Area (HSA) Hospitalizations

COVID-19 Community Levels – Use the Highest Level that Applies to Your Community


New COVID-19 Cases Per 100,000 people in the past 7 days	Indicators	Low	Medium	High
Fewer than 200	New COVID-19 admissions per 100,000 population (7-day total)	<10.0	10.0-19.9	≥20.0
	Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)	<10.0%	10.0-14.9%	≥15.0%
200 or more	New COVID-19 admissions per 100,000 population (7-day total)	NA	<10.0	≥10.0
	Proportion of staffed inpatient beds occupied by COVID-19 patients (7-day average)	NA	<10.0%	≥10.0%

Health Service Areas




# Michigan Lag-adjusted new COVID cases by onset date

New confirmed cases by onset actual and adjusted as of August 16, 2022 (-2 days)




# Adjusted new COVID cases by onset date, recent trends

New confirmed cases by onset actual and adjusted as of August 16, 2022 (-2 days)



# Case Rate Trends by Age Group



Daily new confirmed and probable cases per million by age group (7-day rolling average)



- Case rate trends for all age groups experienced a plateau over the last week
- Case rates by onset date for all age groups are between 117.6 and 303.5 cases per million (through 8/12)
- Case counts and case rates are highest for 30-39-year-olds this week, followed by 20-29-year-olds and the 80+-year-olds

Note: Case information sourced from MDHHS and reflects date of onset of symptoms  
Source: MDHHS – Michigan Disease Surveillance System

# Case Rates by Reported Racial and Ethnic Group




**Updates since last week:**

- Cases per million have plateaued for nearly all reported racial and ethnic groups
- In the past 30 days, 21.8% (↑ 0.3%) of race data and 27.4% (↑ 0.4%) ethnicity data was either missing or reported as unknown


Note: Case information sourced from MDHHS and reflects date of death of confirmed and probable cases.  
Source: MDHHS – Michigan Disease Surveillance System

# Daily average deaths per million people by race and ethnicity have plateaued or are decreasing

## Average daily deaths per million people by race



## Average daily deaths per million people by ethnicity



- Deaths are lagging indicator of other metrics
- Currently, the White population has the highest death rate (1.28 deaths/million)


Note: Death information sourced from MDHHS and reflects date of death of confirmed and probable cases.  
Source: MDHHS – Michigan Disease Surveillance System



# Time Trends – Annual Comparison: Percent Positivity

- Positivity is about half as high as all-time pandemic highs
- However, testing behaviors have shifted, as such comparison year over year should be done so with caution


## 7-day Rolling Average of Positivity



# Time Trends – Annual Comparison: Case Rates

- Case rates (by onset date) are increasing but remain lower than surges from past peaks
- Case rates are, however, similar to August levels in 2020 and 2021


## 7-day Rolling Average of Case Rates




# Time Trends – Annual Comparison: Death Rates

- Death rates (by date of death) are near pandemic all-time lows
- Deaths are lagging indicator, typically trailing case trends by 4 or 6 weeks

## 7-day Rolling Average of Death Rates (per million residents)



# Additional Doses and Booster Coverage



**Note:** Cumulative data and population percentages now include those ages 6 months and older  
**Source:** MDHHS – Michigan Immunizations: COVID-19 Dashboard <https://www.michigan.gov/coronavirus/resources/covid-19-vaccine/covid-19-dashboard>

# Pediatric Vaccination for those 6 months to 5 years: Key Messages

## COVID-19 vaccines are now available for ages 6 months and up

- Everyone 6 months and older should also get an age-appropriate COVID-19 booster, when eligible
- Vaccinations remain the best way to protect from COVID-19, especially from severe disease
- The youngest children can get infected and suffer from severe outcomes
  - Hospital admissions due to COVID-19 for children follow statewide trend with youngest ages accounting for majority of pediatric admissions
  - During the Omicron surge, COVID-19 hospitalizations per capita was higher for those 6 months to 4 years than for children of other ages
  - The proportion of children ages 6 months to 4 years with COVID-19 associated hospitalization were primarily admitted for COVID-19 and over half have no underlying medical conditions
  - Compared to other vaccine preventable diseases, COVID-19 is responsible for more hospitalizations and deaths
  - In Michigan, multisystem inflammatory syndrome in children (MIS-C), over a quarter of all cases have been reported from those under the age of 5
    - Nationally, over 60% of MIS-C cases under the age of 5 have been reported among Non-Hispanic Blacks and Hispanic/Latino
  - COVID-19 is a leading cause of death among all children, including one of the leading causes of death for those under 5 years
    - Based on cumulative total incidence, COVID-19 is the leading cause of death among infectious diseases for people aged 0-19
    - Among children under the age of 5, COVID-19 is the fifth most common of all causes of death
- COVID-19 vaccine has proven to be safe for children in other age groups



# COVID-19 vaccines are now available for ages 6 months and up!

Both the Pfizer and Moderna COVID-19 vaccines are now authorized and recommended for children 6 months and older. Everyone 5 years and older should also get an age-appropriate COVID-19 booster, when eligible.

More than **4,000** providers across Michigan can administer the COVID-19 kids vaccine, including:

Family physicians and pediatricians

Some pharmacies (ages 3+)

Local health departments and federally qualified health centers

Urgent cares (ages 5+)




For more information, visit [Michigan.gov/KidsCOVIDvaccine](https://Michigan.gov/KidsCOVIDvaccine) or talk to a health care provider.






# Hospital admissions due to COVID-19 for children follow statewide trend with youngest ages accounting for majority of pediatric admissions



- Hospital admissions reflect statewide infection trends where admissions are higher during surges of SARS-CoV-2 transmission
- Among those under 18 years of age, the majority of hospital admissions occurred in those 0-11 in Michigan
- Among those under 12 years of age, the majority of hospital admissions occurred in those 0-4 in Michigan

# COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET


March 2020 – March 2022



Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22-23, 2022

Source: COVID-NET, [https://gis.cdc.gov/grasp/COVIDNet/COVID19\\_3.html](https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html). Accessed May 21, 2022.

# Severity of COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET, December 19, 2021 – March 31, 2022 (Omicron period)



BiPAP: bilevel positive pressure, CPAP: continuous positive pressure

Source: COVID-NET data. Accessed May 21, 2022.

# Percent of children ages 6 months–4 years with COVID-19 associated hospitalization with underlying health conditions

■ At least 1 underlying medical conditions    ■ No underlying medical conditions

New Vaccine Surveillance Network, March 2020  
– April 2022

46%

54%

COVID-NET, March 2020 – March 2022

49%

51%


Source: 1. New Vaccine Surveillance Network. Preliminary data as of May 25, 2022, reflecting data from March 2020–April 2022

2. COVID-NET data. Accessed May 21, 2022, reflecting data from March 2020–March 2022

Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22-23, 2022



# Proportion of children ages 6 months–4 years with COVID-19 associated hospitalization who were primarily admitted for COVID-19, COVID-NET March 2020 – March 2022



All children in COVID-NET had a positive SARS-CoV-2 test within 14 days of or during hospital admission. "Primarily admitted for COVID-19" was defined based on the "Reason for admission" field from the case report form. If the chief complaint or history of present illness in the medical chart documents fever/respiratory illness, COVID-19-like illness, or a suspicion for COVID-19, a case is categorized as having COVID-19 as the primary reason for admission. Examples of other non-COVID-19-related reasons for admission seen in this age group include admissions for trauma or inpatient surgeries.

Source: COVID-NET data, Accessed May 21, 2022.

Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22-23, 2022

# Multisystem Inflammatory Syndrome in Children (MIS-C)

## Michigan Surveillance

- Higher community transmissions is followed by higher incidence of MIS-C cases
- 304 cases identified in Michigan: highest numbers have occurred after most recent Omicron surge
- More than 25% of those children are those under 5 years of age
- Black/African American children are disproportionately impacted
- 63.5% (193) children with MIS-C are treated in the ICU
- Among Michigan’s MIS-C cases that were eligible for vaccine (N=113), a majority of children (89.4%, n=101) were unvaccinated
  - **Scientific evidence has shown that unvaccinated kids are at much higher risk of severe MIS-C outcomes<sup>1</sup>**

Age Group	Count	%
<1	11	3.6%
1-4	74	24.3%
5-11	146	48.0%
12-15	54	17.8%
16-20	19	6.3%

Race	Count	%
Black/African American	106	34.9%
Caucasian	146	48.0%
All Others/Unknown	52	17.1%


Ethnicity		
Not Hispanic/Non-Latino	227	74.7%
Hispanic/Latino	27	8.9%
Unknown	50	16.4%

Sources: [MDHHS and MIS-C Data and Reporting](#); Data through 6/30; 1. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021. MMWR Morb Mortal Wkly Rep 2022;71:52–58. DOI: <http://dx.doi.org/10.15585/mmwr.mm7102e1>



# MIS-C patients by race & ethnicity for children and adolescents ages 6 months–17 years by age group

February 1, 2020 – May 31, 2022




Age is missing for 1 case.

Source: CDC data. Accessed June 7, 2022

Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22-23, 2022

# Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children ages 6 months–4 years, FluSurv-NET and COVID-NET, 2017–2022



## Among children ages 6 months–4 years

- Oct 2020–Sep 2021 COVID-19 hospitalization rates were lower than influenza hospitalization rates during 2017–18 through 2019–20 (pre-pandemic) influenza seasons
- Oct 2021–Apr 2022 COVID-19 hospitalization rates were as high or higher than influenza hospitalization rates during 2017–18 through 2021–22 influenza seasons

Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22–23, 2022

Source: Delahoy MJ, Ujamaa D, Taylor CA, et al. [Comparison of Influenza and COVID-19-associated hospitalizations among children < 18 years old in the United States-FluSurv-NET \(October-April 2017-2021\) and COVID-NET \(October 2020-September 2021\)](#). Clin Infect Dis. 2022 May 20;ciac388. doi: 10.1093/cid/ciac388.

# Other Pediatric Vaccine Preventable Diseases:

## Hospitalizations per Year Prior to Recommended Vaccines

	Hepatitis A <sup>1</sup>	Varicella <sup>2</sup> (Chickenpox)	Vaccine-type Invasive Pneumococcal Disease <sup>3</sup>	COVID-19 <sup>4</sup>
Age	5–14 years	0–4 years	0–4 years	6 months–4 years
Time period	2005	1993–1995	1998–1999	Year 1: April 2020–March 2021 Year 2: April 2021–March 2022
Hospitalization Burden (Annual rate per 100,000 population)	<1	29-42	40 <sup>5</sup>	Year 1: 29.8 Year 2: 89.3

<sup>1</sup> <https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5603a1.htm>

<sup>2</sup> Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics*. 2004;114(3):786-792. doi:10.1542/peds.2004-0012

<sup>3</sup> Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. *MMWR Morb Mortal Wkly Rep*. 2005 Sep 16;54(36):893-7. PMID: 16163262.


<sup>4</sup> COVID-NET data, Accessed May 21, 2022.

<sup>5</sup> Vaccine-type invasive pneumococcal disease annual rate for children <5 years in 1998–1999 was 80 per 100,000, of which about 50% were hospitalized.



# COVID-19 death rate among children by age, United States, March 1, 2020—April 30, 2022

- Based on cumulative total incidence, COVID-19 is the **leading** cause of death among **infectious diseases** for people ages 0-19
  - COVID-19 is the **seventh** most common of **all** causes of death for people ages 0-19
- Among people ages 1-4, COVID-19 is the **fifth** most common of **all** causes of death



Based on death certificate data from the National Center for Health Statistics. COVID-19 based on cumulative total incidence of COVID-19 deaths from March 1, 2020-April 30, 2022.

Source: Preprint: Flaxman S, Whittaker C, Semenova E et al. Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States. medRxiv 2022.05.23.22275458; doi: <https://doi.org/10.1101/2022.05.23.22275458>

# COVID-19 is a leading cause of death among children ages 0–19 years

March 1, 2020–April 30, 2022

Age group	Rank of COVID-19 among causes of death
<1 year	4
1–4 years	5
5–9 years	5
10–14 years	4
15–19 years	4

Reported by the CDC at the Meeting of the Advisory Committee on Immunization Practices (ACIP) to discuss immunizations for 6 months to 5 years (Moderna and Pfizer), June 22-23, 2022  
Based on death certificate data from the National Center for Health Statistics. COVID-19 based on cumulative total incidence of COVID-19 deaths from March 1, 2020-April 30, 2022.

Source: Flaxman S, Whittaker C, Semenova E et al. Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States. medRxiv 2022.05.23.22275458; doi: <https://doi.org/10.1101/2022.05.23.22275458>

## Pediatric vaccine preventable diseases:

Deaths per year in the United States prior to recommended vaccines

	Hepatitis A <sup>1</sup>	Meningococcal (ACWY) <sup>2</sup>	Varicella <sup>3</sup>	Rubella <sup>4</sup>	Rotavirus <sup>5</sup>	COVID-19 <sup>6</sup>
Age	<20 years	11–18 years	5–9 years	All ages	<5 years	6 months – 4 years
Time period	1990–1995	2000–2004	1990–1994	1966–1968	1985–1991	Jan 2020–May 2022
Average deaths per year	3	8	16	17	20	86

<sup>1</sup>Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. *J Infect Dis* 2008; 197:1282–8.

<sup>2</sup>National Notifiable Diseases Surveillance System with additional serogroup and outcome data from Enhanced Meningococcal Disease Surveillance for 2015–2019.

<sup>3</sup>Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. *J Infect Dis*. 2000;182(2):383–390.

doi:10.1093/315714

<sup>4</sup>Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. *JAMA* 2007; 296:2155–63.

<sup>5</sup>Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. *J Infect Dis*. 1996 Sep;174


Suppl 1:S5–11.

<sup>6</sup><https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Counts-by-Age-in-Years/3apk-4u4k/data>.



# COVID-19 Vaccine Has Proven to be Safe for Children in Other Age Groups

- In *preauthorization* trials for Pfizer-BioNTech COVID-19 vaccine, vaccinated children aged 5–11 years reported mild to moderately severe local and systemic reactions
  - **No serious vaccination-related events were noted**
- After *authorization* of Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years during October 2021, and administration of approximately 8 million doses, local and systemic reactions after vaccination were reported to VAERS and v-safe for vaccinated children aged 5–11 years.
  - **Serious adverse events were rarely reported**
- Parents and guardians of children should be advised that local and systemic reactions are expected after vaccination and are more common after the second dose



# Peds (< 5 years) Vaccination Progress

## COVID Vaccine Doses Administered by Person's Residence

Dashboard Updated: August 17, 2022. Doses administered are reported according to where the patient lives and the date they were vaccinated. Non-Michigan residents vaccinated in Michigan can be found by selecting "Non-Michigan Resident" in the County drop-down. Providers have 24 hours to report vaccinations to MDHHS. MDHHS pulls the data each morning for cleaning and

Preparedness Region

Local Health Dept. Jurisdiction


County

Provider Type

Dose Number

Michigan

### COVID Doses Administered by County



Data as of:  
8/16/22

Week Ending Date  
12/19/2020 8/20/2022

Sex  
All

Age Group  
under 5 years


Number of COVID Vaccine Doses Administered  
40,283

# Know your risk for serious illness with COVID-19

Check out CDC's list of conditions that may increase your risk for serious illness



Use your COVID-19 Community Level to decide what protective actions to take



[bit.ly/MMWR7133](https://bit.ly/MMWR7133)

AUGUST 11, 2022

**MMWR**



# Guidance to help you make informed decisions to prevent severe COVID-19

1

Know your risk



2

Protect yourself



3

Take action if exposed



4

Take action if you are sick or test positive



[bit.ly/MMWR7133](https://bit.ly/MMWR7133)

AUGUST 11, 2022

**MMWR**

# Take action if you're exposed to COVID-19

## EVERYONE:

Watch for  
symptoms for  
10 days



Wear a mask  
around others  
indoors for 10 days




Test 5 days after  
exposure (or sooner  
if you have  
symptoms)



If positive, follow  
isolation guidance

Take extra  
precautions for 10  
days when around  
people more likely  
to get very sick



[bit.ly/MMWR7133](https://bit.ly/MMWR7133)

AUGUST 11, 2022

**MMWR**